Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Oncology
Published in: International Journal of Clinical Oncology 4/2017

01-08-2017 | Review Article

Biphasic malignant tumours of the abdominal cavity

Authors: L. Max Almond, Adrian T. Warfield, Anant Desai, David Gourevitch, Samuel J. Ford

Published in: International Journal of Clinical Oncology | Issue 4/2017

Login to get access

Abstract

Carcinosarcomas (CS) are uncommon, highly aggressive, biphasic tumours consisting of both sarcomatous and carcinomatous elements. They appear to originate from a common cell of origin, either via transformation from a single premature precursor or conversion of a mature epithelial cell through an epithelial–mesenchymal transition. CS should be considered a unique cancer subtype with cells typically displaying diffuse mitotic activity and widespread atypical mitoses predisposing to early metastasis and a tendency to local recurrence following resection. This review addresses the pathophysiology of CS and discusses its presentation, natural history and management at a variety of sites within the abdominal cavity and retroperitoneum.
Literature
1.
Maeda D, Fujii A, Yamaguchi K et al. (2007) Sarcomatoid carcinoma with a predominant basaloid squamous carcinoma component: the first report of an unusual biphasic tumor of the ureter. Jpn J Clin Oncol 37(11):878–883CrossRefPubMed
2.
Somarelli JA, Boss MK, Epstein JI et al (2015) Carcinosarcomas: tumors in transition? Histol Histopathol 30(6):673–687PubMed
3.
Bitting RL, Schaeffer D, Somarelli JA et al (2014) The role of epithelial plasticity in prostate cancer dissemination and treatment resistance. Cancer Metastasis Rev 33(2–3):441–468CrossRefPubMedPubMedCentral
4.
Schaefer IM, Schweyer S, Kuhlgatz J (2012) Chromosomal imbalances in primary hepatic carcinosarcoma. Hum Pathol 43(8):1328–1333CrossRefPubMed
5.
Matsumoto T, Fujii H, Arakawa A et al (2004) Loss of heterozygosity analysis shows monoclonal evolution with frequent genetic progression and divergence in esophageal carcinosarcoma. Hum Pathol 35(3):322–327CrossRefPubMed
6.
Jin L, Majerus J, Oliveira A et al (2003) Detection of fusion gene transcripts in fresh-frozen and formalin-fixed paraffin-embedded tissue sections of soft-tissue sarcomas after laser capture microdissection and rt-PCR. Diagn Mol Pathol 12(4):224–230CrossRefPubMed
7.
Castilla MA, Moreno-Bueno G, Romero-Perez L et al (2011) Micro-RNA signature of the epithelial-mesenchymal transition in endometrial carcinosarcoma. J Pathol 223(1):72–80CrossRefPubMed
8.
Menon S, Deodhar K, Rekhi B et al (2013) Clinico-pathological spectrum of primary ovarian malignant mixed mullerian tumors (OMMMT) from a tertiary cancer institute: a series of 27 cases. Indian J Pathol Microbiol 56(4):365–371CrossRefPubMed
9.
Amant F, Vloeberghs V, Woestenborghs H et al (2003) Transition of epithelial toward mesenchymal differentiation during ovarian carcinosarcoma tumorigenesis. Gynecol Oncol 90(2):372–377CrossRefPubMed
10.
Dyke JM, Crook ML, Platten M et al (2014) Extravascular migratory metastasis in gynaecological carcinosarcoma. Histopathology 65(3):363–370CrossRefPubMed
11.
Kiuru M, McDermott G, Coit DC et al (2014) Basal cell carcinosarcoma with PTCH1 mutations in both epithelial and sarcomatoid primary tumor components and in the sarcomatoid metastasis. Am J Surg Pathol 38(1):138–142CrossRefPubMed
12.
Piura B, Rabinovich A, Apel-Sarid L et al (2009) Carcinosarcoma of the fallopian tube with metastasis of its epithelial component to the ovary, appendix and omentum. J Obstet Gynaecol 29(6):566–567CrossRefPubMed
13.
Haddad JR, Reyes EC (1970) Carcinosarcoma of the prostate with metastasis of both elements: case report. J Urol 103(1):80–83CrossRefPubMed
14.
15.
Cantrell LA, Blank SV, Duska LR (2015) Uterine carcinosarcoma: a review of the literature. Gynecol Oncol 137(3):581–588CrossRefPubMed
16.
Sreenan JJ, Hart WR (1995) Carcinosarcomas of the female genital tract. A pathologic study of 29 metastatic tumors: further evidence for the dominant role of the epithelial component and the conversion theory of histogenesis. Am J Surg Pathol 19(6):666–674CrossRefPubMed
17.
Artioli G, Wabersich J, Ludwig K et al (2015) Rare uterine cancer: carcinosarcomas. Review from histology to treatment. Crit Rev Oncol Hematol 94(1):98–104CrossRefPubMed
18.
Bansal N, Herzog TJ, Seshan VE et al (2008) Uterine carcinosarcomas and grade 3 endometrioid cancers: evidence for distinct tumor behavior. Obstet Gynecol 112(1):64–70CrossRefPubMed
19.
Felix AS, Stone RA, Bowser R et al (2011) Comparison of survival outcomes between patients with malignant mixed mullerian tumors and high-grade endometrioid, clear cell, and papillary serous endometrial cancers. Int J Gynecol Cancer 21(5):877–884CrossRefPubMed
20.
Vorgias G, Fotiou S (2010) The role of lymphadenectomy in uterine carcinosarcomas (malignant mixed mullerian tumours): a critical literature review. Arch Gynecol Obstet 282(6):659–664CrossRefPubMed
21.
22.
Huang GS, Chiu LG, Gebb JS et al (2007) Serum CA125 predicts extrauterine disease and survival in uterine carcinosarcoma. Gynecol Oncol 107(3):513–517CrossRefPubMedPubMedCentral
23.
Tanner EJ, Leitao MM Jr, Garg K et al (2011) The role of cytoreductive surgery for newly diagnosed advanced-stage uterine carcinosarcoma. Gynecol Oncol 123(3):548–552CrossRefPubMed
24.
Tanner EJ, Garg K, Leitao MM Jr et al (2012) High grade undifferentiated uterine sarcoma: surgery, treatment, and survival outcomes. Gynecol Oncol 127(1):27–31CrossRefPubMed
25.
Nemani D, Mitra N, Guo M et al (2008) Assessing the effects of lymphadenectomy and radiation therapy in patients with uterine carcinosarcoma: a SEER analysis. Gynecol Oncol 111(1):82–88CrossRefPubMed
26.
Yamada SD, Burger RA, Brewster WR et al (2000) Pathologic variables and adjuvant therapy as predictors of recurrence and survival for patients with surgically evaluated carcinosarcoma of the uterus. Cancer 88(12):2782–2786CrossRefPubMed
27.
Cantrell LA, Havrilesky L, Moore DT et al (2012) A multi-institutional cohort study of adjuvant therapy in stage I–II uterine carcinosarcoma. Gynecol Oncol 127(1):22–26CrossRefPubMed
28.
Sutton G, Brunetto VL, Kilgore L et al (2000) A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: a Gynecologic Oncology Group Study. Gynecol Oncol 79(2):147–153CrossRefPubMed
29.
Homesley HD, Filiaci V, Markman M et al (2007) Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study. J Clin Oncol 25(5):526–531CrossRefPubMed
30.
Wright JD, Seshan VE, Shah M et al (2008) The role of radiation in improving survival for early-stage carcinosarcoma and leiomyosarcoma. Am J Obstet Gynecol 199(5):536.e1–536.e8CrossRef
31.
32.
del Carmen MG, Birrer M, Schorge JO (2012) Carcinosarcoma of the ovary: a review of the literature. Gynecol Oncol 125(1):271–277CrossRefPubMed
33.
Dittus C, Fountzilas C, Saha D et al (2014) A rare case of ovarian carcinosarcoma with neuroendocrine differentiation. J Community Support Oncol 12(2):71–74CrossRefPubMed
34.
Cantrell LA, Van Le L (2009) Carcinosarcoma of the ovary a review. Obstet Gynecol Surv 64(10):673–680 (quiz 697) CrossRefPubMed
35.
Silasi DA, Illuzzi JL, Kelly MG et al (2008) Carcinosarcoma of the ovary. Int J Gynecol Cancer 18(1):22–29CrossRefPubMed
36.
Rauh-Hain JA, Diver EJ, Clemmer JT et al (2013) Carcinosarcoma of the ovary compared to papillary serous ovarian carcinoma: a SEER analysis. Gynecol Oncol 131(1):46–51CrossRefPubMed
37.
Rauh-Hain JA, Birrer M, Del Carmen MG (2016) Carcinosarcoma of the ovary, fallopian tube, and peritoneum: prognostic factors and treatment modalities. Gynecol Oncol 142(2):248–254CrossRefPubMed
38.
Cheville JC, Lohse CM, Zincke H et al (2004) Sarcomatoid renal cell carcinoma: an examination of underlying histologic subtype and an analysis of associations with patient outcome. Am J Surg Pathol 28(4):435–441CrossRefPubMed
39.
Eble JN, Sauter G, Epstein JI, Sesterhenn IA, editors. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. 1st. IARC Press; Lyon: 2004. Infiltrating urothelial carcinoma. World Health Organization Classification of Tumours; p. 102
40.
Perimenis P, Athanasopoulos A, Geragthy J et al (2003) Carcinosarcoma of the ureter: a rare, pleomorphic, aggressive malignancy. Int Urol Nephrol 35(4):491–493CrossRefPubMed
41.
Chromecki TF, Cha EK, Fajkovic H et al (2012) The impact of tumor multifocality on outcomes in patients treated with radical nephroureterectomy. Eur Urol 61(2):245–253CrossRefPubMed
42.
Jeldres C, Sun M, Isbarn H et al (2010) A population-based assessment of perioperative mortality after nephroureterectomy for upper-tract urothelial carcinoma. Urology 75(2):315–320CrossRefPubMed
43.
44.
Ozturk H (2015) Multiple carcinosarcomas of the kidney: a case report and review of the literature. Mol Clin Oncol 3(1):212–216PubMed
45.
Maeda D, Fujii A, Yamaguchi K (2007) Sarcomatoid carcinoma with a predominant basaloid squamous carcinoma component: the first report of an unusual biphasic tumor of the ureter. Jpn J Clin Oncol 37(11):878–883CrossRefPubMed
46.
Volker HU, Zettl A, Schon G et al (2008) Molecular genetic findings in two cases of sarcomatoid carcinoma of the ureter: evidence for evolution from a common pluripotent progenitor cell? Virchows Arch 452(4):457–463CrossRefPubMed
47.
Okabayashi T, Shima Y, Iwata J et al (2014) Surgical outcomes for 131 cases of carcinosarcoma of the hepatobiliary tract. J Gastroenterol 49(6):982–991CrossRefPubMed
Metadata
Title
Biphasic malignant tumours of the abdominal cavity
Authors
L. Max Almond
Adrian T. Warfield
Anant Desai
David Gourevitch
Samuel J. Ford
Publication date
01-08-2017
Publisher
Springer Japan
Published in
International Journal of Clinical Oncology / Issue 4/2017
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-017-1153-7

Other articles of this Issue 4/2017

International Journal of Clinical Oncology 4/2017 Go to the issue

Original Article

A mathematical theory of shape and neuro-fuzzy methodology-based diagnostic analysis: a comparative study on early detection and treatment planning of brain cancer

Review Article

Brachytherapy in the treatment of breast cancer

Letter to the Editor

Nomogram predicting long-term survival after the diagnosis of intrahepatic recurrence of hepatocellular carcinoma following an initial liver resection: methodological issues

Original Article

Response to the treatment immediately before nivolumab monotherapy may predict clinical response to nivolumab in patients with non-small cell lung cancer

Original Article

Neutrophil-to-lymphocyte ratio predicts metachronous liver metastasis of pancreatic neuroendocrine tumors

Introduction to Invited Review Articles

Recent advances in targeting DNA-repair pathways for the treatment of ovarian cancer: introduction
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits